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Dilek Odaci Demirkol,d Serdar Ozcelik,f Suna Timur*dg and C. Remzi Becer *c
Over the past decade, there has been a great deal of interest in the integration of nanotechnology and car-
bohydrates. The advances in glyconanotechnology have allowed the creation of different bioactive
glyconanostructures for different types of medical applications, especially for drug delivery and release sys-
tems. Therefore, the use of more efficient biocompatible nanocarriers with high loading capacity, low over-
all toxicity and receptor-mediated endocytosis specificity is still in focus for the enhancement of the thera-
peutic effect. Conjugation of sugar derivatives onto gold nanoparticles presents unique properties that
include a wide array of assembling models and size-related electronic, magnetic and optical properties.
Here, pH-responsive drug-conjugated glycopolymer-coated gold nanoparticles were prepared by
functionalization of gold nanoparticles with thiol-terminated glycopolymers and then subsequent conjuga-
tion of doxorubicin (DOX). Among the four different glycopolymers, their drug release, physicochemical
characterization (spectroscopy, particle size and surface charge) and in vitro bioapplications with four
different cell lines were compared. As a result, pH-sensitive drug delivery via sugar-coated AuNPs
was performed thanks to hydrazone linkages between glycopolymers and DOX. Comparative viability
tests also demonstrated the efficiency of glycopolymer–DOX conjugates by fluorescence cell imaging.
The obtained results reveal that AuNP homoglycopolymer DOX conjugates (P4D) have significant
potential, especially in human neuroblastoma cells in comparison to cervical cancer cells and lung
cancer cells.
Introduction
Advances in the nanotechnology field have been guided by
an increasing demand for nanotools that can be applied by
way of therapy and non-invasive diagnostics, especially in the
field of biomedicine. In the past few years, many different
materials have been proposed as biomedical architectures,
which have been developed ambitiously for use in disease di-
agnosis and therapy. Along this purpose, organic-based and
metallic-based materials and their composite versions have
been studied by numerous researchers and novel techniques
for creating these materials have been established to increase
the efficacy, robustness, stability or other desirable physical
and chemical properties. Among them, organic–inorganic hy-
brids,1,2 polymers,3,4 liposomes,5,6 hydrogels,7 emulsions8
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Design, System, Application
Glycopolymer coated gold nanoparticles have been designed as pH responsive anticancer drug carriers through biological media and to release the drug
under acidic conditions. Functional ‘Sweet or Sugar Coated Gold’ nanostructures were fabricated via functionalization of gold nanoparticles with thiol-
terminated glycopolymers and then doxorubicin as an anticancer drug model was conjugated onto the surfaces via pH-sensitive hydrazone bonds. After
characterization of the resulting nanoparticle drug conjugates, their cytotoxic properties and cell affinities towards various cancerous cell lines were evalu-
ated. This design could be adapted to the controlled-release of various chemotherapeutics and these ‘Sweet nano structures’ could be applied for both im-
aging and therapeutic applications.
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and metallic-based functionalized materials9,10 have been
presented with outstanding abilities.
Metal nanoparticle-based materials are appealing alterna-
tives to fluorescence- or radiolabelled protein substrates, ow-
ing to their photo-stability, facile synthesis and ability to con-
jugate with biological molecules.11,12 Among these metallic
nanoparticles, gold nanoparticles have paved the way thanks
to the advantages such as chemical inertness, facile surface
functionalization, amenable surface plasmon resonance and
suitable optical properties for imaging.13–17
Concomitantly, there are other significant issues for NPs
consisting of their stability and improvement of enhanced
permeability and retention effect (EPR) without facing renal
elimination and recognition by phagocytes.18 Hence,
functionalization of AuNPs by constructing a core–shell archi-
tecture with polymeric layers including other recognition ele-
ments to facilitate the uptake of NPs has gained attention. To
enable these specialties for AuNPs, glycofunctionalization has
been a breakthrough both in surface modification for cell ad-
hesion and potential anticancer activities applied with radia-
tion therapy.19,20 Furthermore, prior to their modification on
the surface of NPs, glyco-based structures as supramolecules
were synthesized and used in bioapplications, successfully.21
The specific recognition properties of carbohydrates and
unique physiochemical properties of gold nanoparticles are a
desirable combination for the creation of multivalent nano-
particles for the treatment of chemotherapy/radiotherapy and
fluorescence imaging. In our previous study, we presented
polymethacrylic acid (PMAA) coated AuNPs and their post-
modification with doxorubicin (DOX) to create a drug delivery
system based on a pH-responsive manner.22 Instead of direct
coating via thiol linkages, an additional polymer layer cov-
ered the surface of AuNPs before conjugation of DOX mole-
cules and post-modified AuNP–PMAA particles via pH-
sensitive hydrazone bonds.
Herein, we successfully synthesized mannose (Man)
tagged AuNPs by covering the metallic core with methacrylic
acid derivatives as a toolbox for pH-sensitive drug delivery.
After defining bioconjugates in terms of size, surface charge
and spectrophotometric properties, they were applied to four
different cell lines including three cancerous and one healthy
ones and their cytotoxic properties and cellular uptake were
evaluated by fluorescence cell imaging. The efficacy of
polymer-coated AuNPs with Man was also tested in a compre-
hensive comparison by using only polymer coated AuNPs
without Man and free DOX.
Results and discussion
Synthesis of D-mannose methacrylate glycomonomer
(ManMac)
The reversible addition-fragmentation chain transfer (RAFT)
polymerization is a commonly used technique to polymerize
methacrylates. Hence, mannose methacrylate glycomonomers
were polymerized via RAFT polymerization. Copper-catalyzed
azide-alkyne cycloaddition (CuAAC) was performed for the
synthesis of mannose methacrylate monomers. Azide func-
tionalized methacrylate was clicked to mannose alkyne, suc-
cessfully. The CuAAC click reaction was carried out in the
presence of CuSO4·5H2O and (+)-sodium L-ascorbate as a cata-
lyst system in a MeOH/H2O mixture at room temperature for
24 h. The click reaction was monitored and confirmed by 1H-
NMR, 13C-NMR and ESI-MS.
As depicted in Fig. S1,† the new peak at 8.02 ppm
appeared due to the formation of a triazole ring, which con-
firmed the click reaction between azide and alkyne groups.
In addition, the existence of D-mannose C-1 peaks at 102.3 &
104.7 ppm revealed that the monomer is an anomeric mix-
ture according to the 13C-NMR data. In the ESI-MS spectra,
there is a clear peak at 387.4 m/z that corresponds to the mo-
lecular weight of the mannose glycomonomer with a theoreti-
cal mass of 387.2 m/z. The product was obtained as a white
solid with a 44% yield. The main reason behind the low yield
is the poor solubility of 3-azidopropyl methacrylate in the
MeOH/H2O mixture which affects the efficiency of purifica-
tion on the column.
Synthesis of homo/co-polymers via RAFT
RAFT polymerization of the homo/co-monomers was carried
out in the presence of 2-cyano-2-propyl benzodithioate
(CPBDT) as a RAFT agent and 4,4′-azobis-(2-methylpropio-
nitrile) AIBN as an initiator in a methanol and water mixture
(2 : 1) at 70 °C for 12 h. Briefly, a Schlenk tube was charged
with targeted monomers (MAA, OEGMA and ManMac) (in to-
tal, 100 eq.), CPBDT (1 eq.), AIBN (0.1 eq.) and solvent (3.0
mL), which was degassed by gently bubbling argon gas for 30
min. The Schlenk tube was sealed and the mixed solution
was allowed to polymerize. The RAFT homo/copolymeriza-
tions have been achieved with good control indicated by the
narrow dispersity indices in accordance with the targeted mo-
lar mass. After purification, DMF SEC analysis based on
PMMA standards revealed a single peak of each polymer
without any considerable tailing or shoulder with an appar-
ent Mn = 12.1–32.7 kDa and Mw/Mn = 1.18–1.21 (Table 1).
However, some obtained polymers including carboxylic acid
moieties showed a small amount of tailing in the low molar
mass range in the SEC analysis. This is most likely due to the
interaction of the carboxylic acid moieties of the polymers
with the SEC column's packing material. In addition, the
obtained polymer containing OEGMA presented a small
shoulder due to possible coupling reactions. OEGMA was
used to prepare a reference material (P3) due to its biocom-
patibility and hydrophilicity. Additionally, polymers
containing OEGMA are suitable for biological applications
since they do not trigger an immune response. In order to
understand the difference in lectin binding and cell recogni-
tion, the composition of the glyco-copolymers was designed
to have a minimum of 50% of the carbohydrate units of the
overall repeating units.
The conversion values of monomers were calculated using
the 1H NMR data by comparing the integrated signal
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intensity due to the aromatic protons of the RAFT agent at
7.8–7.9 ppm with the vinyl protons of monomers at 5.8–6.2
ppm. 1H NMR characterization revealed that quantitative
conversions were achieved for each monomer. The Mn,SEC cal-
culated by SEC measurement is slightly higher or lower than
the theoretical molar mass mainly due to the different struc-
tures of the obtained polymers according to PMMA calibra-
tion standards. The theoretical number average molar mass
of the synthesized polymers, Mn,Theo, was calculated by using
the equation: Mn,Theo = ([M]0/[RAFT]0 × conversion × Mmon) +
MRAFT, where [RAFT]0 is the initial RAFT agent concentration,
[M]0 is the initial monomer concentration, Mmon is the mono-
mer molecular weight, and MRAFT is the RAFT agent's molec-
ular weight.
Reduction of the RAFT end group of homo/co-polymers
The RAFT agent terminal group of the obtained
glycopolymers was reduced to a thiol-terminal in order to im-
mobilize the synthesized polymers onto gold nanoparticles in
the presence of aqueous NaBH4.
1H NMR and SEC were used
to analyze the polymers before and after reduction. The dis-
appearance of the aromatic protons of the RAFT agent at 7.8–
7.9 ppm after treatment indicated that all end groups in the
CPBDT units have been successfully reduced.
As depicted in Fig. 1 and S2,† no obvious changes in the
SEC traces were observed and the Mn,SEC was exactly similar
to that before treatment according to RI detection of SEC.
However, variable wavelength detection of SEC at 308 nm did
not show any significant peak after treatment suggesting that
the polymer end groups are successfully modified to –SH.
Moreover, the color of polymers which is due to the RAFT
agent changed from pink to white after the successful cleav-
age of the RAFT end group.
Preparation of glycopolymer-substituted AuNPs
Prior to polymer functionalization, AuNP solution was
centrifuged. The supernatant was removed and replaced with
the same volume of water. Then, the polymer coated gold
nanoparticles were prepared by mixing the polymer and
AuNPs in the dark overnight. Firstly, the obtained polymer-
coated AuNPs were characterized via DLS and UV/vis spectro-
scopy in terms of investigating the size and surface plasmon
resonance maximum band (SPRmax) value change. The
SPRmax band of AuNPs is usually dependent on the nanopar-
ticle size, shape, aggregation and also their dielectric environ-
ment. As seen in Fig. 2 and S4,† the position of the SPRmax
band shifted to higher wavelengths due to adsorption of the
polymer onto the surface. Moreover, the UV absorbance
peaks confirmed that the AuNPs coated with thiol-terminated
polymers were still spherical in shape and also did not show
any aggregation due to the absence of any large broad shift
in the UV absorbance. The general scheme of the reactions
related to the synthesis of AuNPs coated with glycopolymers
is provided in Scheme 1.
Polymer-substituted AuNPs were characterized in terms of
size and zeta potential by using DLS. There were significant
increases in the hydrodynamic volume between AuNPs and
polymer–AuNPs, indicating the successful immobilization of
the polymers onto the surface. As depicted in Fig. 2 and S3,†
the size of the gold nanoparticles after coating with polymers
increased from 55 ± 0.2 nm to 94 ± 0.7–101 ± 0.9 nm with the
dispersity index (Đ) between 0.15 and 0.22, signifying a nar-
row particle size distribution. Furthermore, the negative zeta
potential of AuNPs has changed depending on the nature of
Table 1 Summary of RAFT polymerizations of ManMac, MAA and OEGMA; number average molar mass (Mn) and molar mass distribution (Đ) of
polymers
Code Composition Mn,Theo (g mol
−1) Mn,GPC (g mol
−1) Đ
P1 PĲ(MAA)96) 8400 12 100 1.18
P2 PĲ(ManMac)46-r-(MAA)44) 21 800 24 600 1.21
P3 PĲ(ManMac)45-r-(OEGMA)43) 30 500 29 400 1.19
P4 PĲ(ManMac)94) 37 300 32 700 1.21
Fig. 1 A) SEC analysis via RI detection; B) via VWD; C) 1H NMR
characterization of the synthesized P2 homopolymer before and after
reduction of the RAFT group.
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Fig. 2 A) UV/vis spectroscopy characterization of AuNPs and the obtained AuNPs-P2 nanoparticles; B) DLS measurements of the synthesized
AuNPs-P2 and AuNPs; C) TGA measurements of AuNPs and the obtained AuNPs-P2; D) TEM images of the obtained P2-coated AuNPs.
Scheme 1 The overall synthetic strategy for the preparation of glycosylated AuNPs.
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the polymer moieties. For instance, even though the magni-
tude of the negative zeta potential of PĲMAA)-coated AuNPs
increased from −26.9 ± 0.2 mV to −41.5 ± 2.3 mV due to the
deprotonation of the carboxyl group (RCOOH ↔ RCOO− +
H+) in aqueous solution, the negative zeta potential of
PĲManMac)-coated AuNPs decreased to −24.0 ± 1.5 mV.
According to the transmission electron microscopy (TEM) im-
ages (Fig. 2 and S6†), the size of the polymer-coated gold
nanoparticles ranged between 57 ± 1.8 and 61 ± 1.7 nm. The
average size of the monodisperse nanoparticles is summa-
rized in Table 2.
In order to determine the amount of the polymer
immobilized onto AuNPs, thermal gravimetric analysis (TGA)
was utilized to analyze each material's thermal profile. As
seen in Fig. 2 and S5,† each polymer-coated AuNP exhibited
mass loss until approximately 650 °C due to the decomposi-
tion of the polymer onto the surface and the remaining frac-
tion was the Au core of the synthesized nanoparticles which
was unaffected even at temperatures as high as 650 °C. It was
observed that polymer-substituted AuNPs contained approxi-
mately 86.2–88.7% polymer.
Characterization of Man tagged polymer conjugates
As stated in the Introduction section, monosaccharide
modified glycoconjugates as nanotools are an advancing
route. These glycoconjugates can also be functionalized to
metallic or polymeric NPs by active groups. In this work,
Man tagged AuNP/polymer core–shell structures with differ-
ent ratios of MAA, OEGMA and ManMac were investigated
for drug delivery studies by using DOX as the model
chemotheurapeutic anticancer agent.23 Accordingly, three
different bioconjugates with DOX including P2D, P3D and
P4D were prepared. These novel conjugates were also com-
pared in reference to another polymer coated AuNP particle
(PMAA coated AuNP-P1D) which was shown in our previous
work.22 Within that work, it was already illustrated that
these polymer covered AuNPs could be potential carriers of
DOX and be pH-sensitive by utilizing the hydrazone bond.
Herein, the synthesis of glyconanoparticles was performed
successfully with a few modifications according to the pre-
vious work.
Initially, the binding capacity of each particle was de-
termined via a DOX standard graph between 2.5–100 μM
with the equation y = 0.006x − 0.009 (R2 = 9996). The
DOX binding capacities of each conjugate are as follows:
41% for P1D, 25.6% for P2D, 32% for P3D, and 33.6%
for P4D. As can be seen from the binding capacities, the
structural changes of the polymer-coated AuNPs affected
DOX binding in relation to the conjugation strategy. P1D,
which has the most DOX amount, was obtained by the
well-known EDC/NHS coupling under mild conditions due
to the small functional moieties coming from MAA. Con-
comitantly, P2D, P3D and P4D conjugations were carried
out by CDI coupling due to the urethane linkages which
may be more sensitive with respect to EDC/NHS coupling.
Moreover, this revealed the different Man amounts with
more pendant –OH groups, which can be used effectively
in the CDI method.
Particularly in P3D, which showed similar binding to P4D,
there is less Man in comparison to OEGMA that contains ad-
ditional –OH groups by inducing more DOX binding with re-
spect to P2D conjugation. Afterwards, the same concentra-
tions of DOX were utilized for the rest of the work. The
spectrophotometric properties were investigated by
presenting the normalized absorbance of each spectrum be-
tween 350–600 nm. According to Fig. 3, small shifts to 500
nm for the newly synthesized conjugates were observed rela-
tive to the maximum absorbance peak of DOX after conjuga-
tion. Additionally, these peaks are also beneficial to the sub-
sequent drug release studies for measuring the absorbance of
the release media.
As the next characterization step, the hydrodynamic parti-
cle size distributions and surface charges of each bio-
conjugate were examined. DLS provided results in terms of
RH, which is a hypothetical measure of the hydrodynamic ra-
dius of NPs in colloidal dispersions, to predict and control
the fate of these NPs in cell media. Table 3 shows the differ-
ences in particle size and zeta potential between polymer
coated particles and DOX-loaded bioconjugates. The DLS
data confirmed that the DOX conjugated particles demon-
strated the largest particle size distribution; the size of the
Table 2 Summary of DLS, UV/vis spectroscopy and TEM characterization
results of the glycopolymer-coated AuNPs
Sample
DLS TEM
size
(nm)
Zeta
potential
(mV)
SPRbandĲmax)
(nm)Dh (nm) Đ
AuNPs 55 ± 0.2 0.11 43 ± 1.2 −26.9 ± 0.2 519
AuNPs-P1 101 ± 0.9 0.15 57 ± 1.8 −41.5 ± 2.3 521
AuNPs-P2 94 ± 0.4 0.21 59 ± 2.1 −19.4 ± 7.3 522
AuNPs-P3 96 ± 0.8 0.22 61 ± 1.7 −27.8 ± 2.8 524
AuNPs-P4 95 ± 0.6 0.18 60 ± 2.4 −24.0 ± 1.5 523
Fig. 3 Normalized absorbance spectrum of AuNP/polymer–DOX core–
shell particles and free DOX (all samples are at 10 μM DOX
concentration).
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negatively charged structure of Man tagged AuNPs decreased
after bioconjugation.
Over the past decade, the advanced drug carrying nanotool
called “trojan horse” has been developed with different strat-
egies.24 In particular, pH-sensitive macromolecular polymeric
structures,25 vesicular systems26 or metallic NPs27 were stud-
ied. Herein, Man tagged AuNP/polymer particles linked to
DOX molecules with pH-sensitive hydrazone bonds were eval-
uated for their in vitro release profiles, in order to investigate
the potential use of these particles as delivery carriers. One of
the main characteristic features of tumor sites is that they
have a slightly acidic microenvironment.28
Many of the pH-sensitive bonds between the drug and the
carrier, which are formed via a typical hydrazone linkage,
were evaluated at pH 5.3 as a model of the extracellular pH
environment of cancer cells and at pH 7.4 as a model of the
environment of healthy cells.29 As shown in Fig. 4, the drug
release kinetics of DOX were much faster in an acidic pH en-
vironment (pH 5.3) than in neutral pH (pH 7.4) for all sam-
ples. DOX released from AuNPs was more controllable in
comparison to free DOX, which reached 100% release after
72 h. On the other hand, under slightly alkaline conditions
(pH 7.4) free DOX exhibited fast release while the cumulative
release of conjugated particles was slow. In particular, a neg-
ligible amount of drug release from the P4D conjugate in
physiological pH (pH 7.4) supports that it could be a good
candidate as a pH responsive drug carrier. As a result, the
slow drug release characteristics at neutral pH and increased
drug release in acidic environments ensure AuNP–DOX bio-
conjugates to be promising drug carriers to improve intracel-
lular drug release in the acidic microenvironment of most tu-
mor types.
Effects of AuNPs on cell viability
The effects of the four different AuNPs were investigated
using human cervix adenocarcinoma (HeLa), human lung
carcinoma (A549), human neuroblastoma cells (SH-SY5Y),
and monkey kidney epithelial cell line (Vero) cell lines
(Fig. 5A). P1, P2, and P3 inhibited the growth of HeLa
cells whereas P4 had no effect on cell viability. The inhibi-
tory effects of P1 were similar to those of P2 and P3 at
higher doses. On the other hand, at lower doses, P1
slightly decreased the cell viability. In the case of A549
cells, a dose dependent decrease in cell viability was ob-
served for P2 and P3. There was no decline in cell viabil-
ity in SH-SY5Y and Vero cells. Surprisingly, induction of
cell growth was observed in the SH-SY5Y cell line. As a re-
sult, 50 μg mL−1, 10 μg mL−1, 10 μg mL−1 and 250 μg
mL−1 non-toxic doses were chosen for P1, P2, P3 and P4,
respectively, and used for DOX bioconjugation.
Effects of DOX conjugated AuNPs on cell viability
In this study, we selected different tumor cells which may
simulate different diseased tissues in traditional 2D cell
cultures as the first step before animal and preclinical
studies. Literally, this novel work gives an idea of the sim-
ple characteristics of each used cell line due to the possi-
ble interaction with the Man tagged nanocarriers, since
there is not a comprehensive comparison related to man-
nose specific cells. However, it is known that carbohydrate
moieties have been beneficial labels thanks to the altered
glycosylations of cancerous tissues. After determining the
individual effects of AuNPs, the concentrations that have
no effect on cell viability were used in the following DOX
conjugation (Fig. 5B). There were no changes in cell via-
bility for DOX-conjugated AuNPs (P1D, P2D, P3D, and
P4D) and free DOX in both HeLa and A549 cells lines. In
the previous work, it was also observed that HeLa cells
were not affected by AuNP–DOX particles up to 1 μM con-
centration.22 In the case of A549 cells which contain Man
receptors all over the cell surface, a study which used
DOX loaded and Man tagged polymeric micelles supports
our findings with an inhibitory concentration level of 5.2
μM DOX for 72 h.30 There was a dose dependent decrease
in cell viability for SH-SY5Y and Vero cells. In the case of
SH-SY5Y, DOX-conjugated AuNPs were more effective than
free DOX except for P2D due to the high release rate of
DOX outside the cells and the possibility of a lower DOX
amount for each particle which was explained in the char-
acterization part. The efficiency of other particles in SH-
SY5Y cells indicates that this type of neuroblastoma cell is
more capable of working with Man tagged formulations.
However, free DOX was more effective in decreasing the
cell viability in Vero cells compared to conjugated AuNPs.
These valuable results indicate that these nanoparticles
may also succeed in brain cancer targeting due to the
mannose functionalization enabling them to cross the
blood–brain barrier as shown in a previous study.31
Table 3 Physicochemical characteristics of bioconjugates
Sample Particle size (nm) Zeta potential (mV)
P1D 147 ± 25 −22.7 ± 12
P2D 239 ± 7.8 −9.5 ± 0.9
P3D 211 ± 27.1 −12.3 ± 1.3
P4D 171 ± 34.8 −10.9 ± 0.5
Fig. 4 Cumulative drug release graph of free DOX at pH 5.3 and pH
7.4 and AuNP/polymer–DOX bioconjugates at pH 5.3 and pH 7.4 for 72
h at 37 °C.
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Cellular uptake
It is possible to use the intrinsic fluorescence emission of
DOX to monitor drug localization in cells.29 We investigated
whether DOX could enter cells when conjugated to carrier
AuNPs (Fig. 6). Cellular internalization of DOX was observed
in all conjugates. The incubation times of free DOX and all
glycopolymer conjugates were kept at 3 h, however images
were taken after 30 min and 3 h, sequentially to observe the
drug release effectiveness of the conjugates by means of time
without the fixation of cells.
By using confocal laser microscopy, the DIC images were
also included to monitor the morphology of neuroblastoma
cells (SHSY-5Y) and were overlaid with the fluorescence im-
ages. As can be seen from Fig. 6, all samples are near, around
and/or stacked on cell membranes after 30 min. Moreover,
DOX and DOX conjugated glycopolymer coated AuNPs were
found in the cytoplasm and interlocalized to the environment
of the nucleus. This issue can be linked to the delivery of
DOX due to the breakage of linkages in cytoplasmic media
which can generally occur in endosomes after endosomal up-
take of nanoparticles. In accordance with the in vitro drug
Fig. 5 The effects of (A) AuNPs and (B) DOX conjugated AuNPs with free DOX on cell viability for 24 h [NT: non-treated cells. Bars represent ±SD,
(n = 4)].
Fig. 6 Confocal laser microscopy images of free DOX and P1D, P2D, P3D and P4D conjugations after treatment of samples for 30 min and 3 h,
respectively. Bright-field images were taken in DIC mode and fluorescence images were taken by using 488 nm laser. All images were obtained
with 100× magnification.
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release study, this successful experiment indicates that free
DOX in cancer cell media, which have a lower pH than that
in healthy cells, was spread more effectively. These data sug-
gest that AuNPs are membrane permeable and have no effect
on DOX sub-cellular localization even in concentrations un-
der 1.0 μM DOX as the model cancer drug.
Conclusions
Incorporating the biological properties of carbohydrates
into nanostructured materials has attracted much atten-
tion due to their crucial role in bio-recognition processes
at a molecular level and also their functional role in liv-
ing systems. Hence, glycopolymer-coated gold nano-
platforms would be a great benefit as drug carriers to en-
hance the exposure of target sites to drugs. In this study,
thiol-terminated glycopolymers have been prepared by
RAFT and then grafted onto AuNPs. Subsequently, an anti-
cancer drug doxorubicin was conjugated to glycopolymers
by a pH-sensitive hydrazone linkage in the presence of
cysteine and a cross-linker. Following the conjugation
steps, it has been observed that the size and surface
charge of glycopolymers changed after DOX conjugation
and the drug release profiles proved the efficient
sustained release of DOX from the glycopolymeric
branches of the AuNPs. In terms of cellular viability, espe-
cially for SH-SY5Y neuroblastoma cells, glycopolymer con-
jugates (P4D) showed their therapeutic effect and a higher
toxicity to cancer cell lines compared to healthy cell lines
(Vero). These AuNP/glycopolymer conjugates as potential
carriers with sustainable release of DOX may create a
doorway to the next step of improving 3D cell cultures
and/or in vivo animal studies related to a neuroblastoma
type of cancer.
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